# 04_QA_REPORT --- PP-0179 Lauren Classification

## Identity

-   **PP ID:** PP-0179
-   **Title:** Lauren Classification
-   **QA Report ID:** QA-PP-0179
-   **Version:** 1.0.0
-   **QA Date:** 2026-08-09
-   **Status:** PASS --- GOLD --- READY FOR INTEGRATION

## QA Executive Summary

PP-0179 was produced after the complete Decision Batch was approved and
locked.

The package was checked against:

-   CORE_WORKING_RULES v1.6;
-   FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.0;
-   PP Registry;
-   approved Discussion depth/format reference;
-   supplied gastric cancer clinical source materials;
-   adjacent package ownership.

The absolute full-depth rule was applied. The package was not compacted
to make it shorter than the approved Gold reference standard.

------------------------------------------------------------------------

# Layer 1 --- Content QA

## 1.1 Scope respected

**PASS**

The package is dedicated to Lauren Classification.

It does not silently expand into:

-   general histopathology;
-   WHO taxonomy;
-   grading;
-   staging;
-   molecular classification;
-   biomarker testing;
-   hereditary genetics;
-   treatment algorithms.

## 1.2 Completeness

**PASS**

The CKO contains:

-   metadata;
-   educational objectives;
-   scope;
-   included/not included;
-   **40 independent clinical knowledge blocks**;
-   patient explanations;
-   clinical importance;
-   key concepts;
-   evidence anchors;
-   common misconceptions;
-   key messages;
-   knowledge graph;
-   revision history.

The block structure deliberately preserves full depth rather than
compressing multiple clinically distinct questions into short prose.

## 1.3 Core category coverage

**PASS**

The package explicitly covers:

-   intestinal;
-   diffuse;
-   mixed.

No core Lauren category has been omitted.

## 1.4 Boundary clarity

**PASS**

The package clearly distinguishes Lauren Classification from:

-   PP-0178 Histopathologic Classification;
-   WHO Classification;
-   tumor grade;
-   histologic differentiation;
-   TNM staging;
-   molecular classification;
-   biomarker testing.

------------------------------------------------------------------------

# Layer 2 --- Clinical QA

## 2.1 Clinical accuracy

**PASS**

Core morphology claims are grounded in NCCN and NCI source materials.

NCCN describes intestinal and diffuse histologic types and provides
characteristic morphologic features. fileciteturn28file6

## 2.2 Guideline consistency

**PASS**

The package uses NCCN v2.2026 as the principal current gastric-cancer
guideline for:

-   histologic subtype;
-   pathologic review;
-   intestinal/diffuse morphology;
-   relationship between histology and biomarker context.

NCCN explicitly notes that intestinal/diffuse subclassification may have
implications for therapy and reports different HER2 positivity rates
across subtypes. fileciteturn28file15

## 2.3 Prognostic overclaim control

**PASS**

The package does not claim that:

-   diffuse automatically means poor prognosis;
-   intestinal automatically means good prognosis;
-   Lauren subtype alone predicts an individual patient's outcome.

## 2.4 Treatment overclaim control

**PASS**

The package does not provide treatment algorithms or prescribe therapy
based on Lauren subtype.

It only permits source-supported contextual statements about histologic
subtype and biomarker/treatment relevance.

## 2.5 Hereditary overclaim control

**PASS**

Diffuse/signet-ring morphology is discussed as a hereditary-context clue
only.

No CDH1 diagnostic rule, germline testing algorithm or hereditary
treatment recommendation is introduced.

## 2.6 Specimen limitation

**PASS**

The package explicitly explains why limited biopsy tissue can fail to
represent the full morphology of a tumor.

NCI HDGC PDQ supports the possibility that very superficial biopsy can
miss diffuse/signet-ring disease. fileciteturn28file17

------------------------------------------------------------------------

# Layer 3 --- Educational QA

## 3.1 Patient friendliness

**PASS**

Technical terms are introduced with patient-facing explanations.

## 3.2 Terminology

**PASS**

The package clearly differentiates:

-   Lauren type;
-   histologic type;
-   grade;
-   differentiation;
-   stage;
-   WHO classification;
-   molecular classification;
-   biomarkers.

## 3.3 Logical flow

**PASS**

The CKO follows:

**definition**

→ **why classification is used**

→ **how classification is assigned**

→ **intestinal**

→ **diffuse**

→ **mixed**

→ **heterogeneity/specimen limitations**

→ **classification relationships**

→ **clinical relevance**

→ **limitations**

→ **patient interpretation**.

## 3.4 Misconception control

**PASS**

Fifteen common misconceptions are explicitly addressed.

## 3.5 Full-depth compliance

**PASS --- ABSOLUTE**

The package follows the standing rule:

> **Approved Gold reference depth is the minimum. Never compact or
> shorten the artifact. Equal depth is required; deeper is permitted
> where clinically justified.**

No "concise version" or compressed package was produced.

------------------------------------------------------------------------

# Layer 4 --- Governance QA

## 4.1 Four-artifact structure

**PASS**

Exactly four governed Markdown artifacts are included:

1.  01_CKO.md
2.  02_KNOWLEDGE_PASSPORT.md
3.  03_PRIMARY_EVIDENCE_PACKAGE.md
4.  04_QA_REPORT.md

## 4.2 Gold Specification compliance

**PASS**

The artifact structure follows the locked Gold Population Package
Specification v1.0. fileciteturn27file15turn27file17

## 4.3 Source-first compliance

**PASS**

The PP identity, scope, adjacent ownership and clinical evidence were
established from the project Source Files before production.

## 4.4 User-controlled sequence

**PASS**

PP-0179 was produced only after the user's explicit request and
approval/lock of its Decision Batch.

No automatic advancement to PP-0180 occurred.

## 4.5 Boundary compliance

**PASS**

The final production Boundary uses exactly the required ownership
structure:

-   Core
-   Supporting
-   Explicitly Excluded
-   Delegated-to PP

CORE_WORKING_RULES requires this Boundary to accompany the final Gold
ZIP and QA status. fileciteturn27file8

## 4.6 ZIP naming

**PASS**

The package filename contains:

-   PP number;
-   package title.

## 4.7 Repository readiness

**PASS**

The package is ready for integration.

------------------------------------------------------------------------

# QA Traceability Matrix

  Requirement                          Result
  ------------------------------------ --------
  Correct PP identity                  PASS
  Approved scope used                  PASS
  Full-depth rule                      PASS
  CKO structure                        PASS
  Knowledge Passport                   PASS
  Primary Evidence Package             PASS
  QA Report                            PASS
  Intestinal category                  PASS
  Diffuse category                     PASS
  Mixed category                       PASS
  Lauren vs histopathology             PASS
  Lauren vs grade                      PASS
  Lauren vs differentiation            PASS
  Lauren vs TNM                        PASS
  Lauren vs WHO                        PASS
  Lauren vs molecular classification   PASS
  Biomarker boundary                   PASS
  Prognostic overclaim control         PASS
  Treatment overclaim control          PASS
  Hereditary boundary                  PASS
  Evidence traceability                PASS
  Knowledge Graph                      PASS
  Boundary                             PASS
  Four-artifact ZIP                    PASS
  ZIP filename includes title          PASS
  Repository readiness                 PASS

# Final Boundary

**Boundary: Core = Lauren Classification as a morphology-based framework
for gastric adenocarcinoma, including its purpose and place in
pathology, intestinal, diffuse and mixed categories, the morphologic
concepts underlying these categories, signet-ring/poorly cohesive and
infiltrative morphology as relevant classification context, mixed
features and tumor heterogeneity, specimen-related limitations, and the
relationship of Lauren classification to histopathology, tumor grade,
histologic differentiation, WHO classification, TNM staging, molecular
classification and selected biomarker context; Supporting =
biopsy-versus-resection implications, linitis plastica as a diffuse-type
context, selected source-supported associations between Lauren subtype
and molecular/biomarker features, pathology review in difficult or
discordant cases, historical/conceptual context, and patient-facing
interpretation of Lauren terminology; Explicitly Excluded = detailed
endoscopic diagnosis, biopsy technique, general histopathologic
characterization already owned by PP-0178, exhaustive WHO taxonomy,
detailed WHO diagnostic criteria, tumor-grade methodology,
histologic-differentiation methodology, complete TNM staging, biomarker
testing/scoring, molecular-classification methodology, NGS methodology,
genomic interpretation, EBV testing methodology, hereditary/CDH1
genetics, individualized prognosis, and treatment-selection algorithms;
Delegated-to PP = PP-0178 Histopathologic Classification, PP-0037 WHO
Classification of Gastric Cancer, PP-0038 Tumor Grade, PP-0039
Histologic Differentiation, PP-0180 Gastric Cancer Molecular
Classification, PP-0181--PP-0187 Biomarker/NGS Testing, PP-0189 Genomic
Test Results / How to Read a Molecular Report, PP-0190--PP-0191
Biomarker-guided Treatment, PP-0168 EBV-associated Gastric Cancer + EBV
Testing, hereditary gastric-cancer/HDGC packages, and dedicated staging,
pathology-report, endoscopic and treatment packages.**

# Final QA Decision

## **PASS --- GOLD --- READY FOR INTEGRATION.**

The PP-0179 package is complete, source-grounded, full-depth,
structurally compliant, boundary-controlled, and ready for integration.
